Sanofi shares fell after the company said Belen Garijo, the chief executive of Germany’s Merck KGaA, would succeed Paul ...

The sudden departure stands in contrast to other EU pharma leaders who have been given much longer transitions in recent ...

Sanofi is replacing Paul Hudson as CEO, amid questions about which medicines will drive the company's growth in the future.

Sanofi said Belen Garijo, the chief executive of Merck KGaA, would succeed Paul Hudson as CEO after the board of directors decided not to renew Hudson's mandate.

Sanofi sold its controlling stake in the drugmaker’s consumer-health unit last year, meaning it’s now entirely reliant on innovative prescription medicines.

Sanofi abruptly replaced Chief Executive Officer Paul Hudson after a massive research spending boost failed to deliver rapid results, appointing its first female leader, Merck KGaA’s Belén Garijo.

Sanofi’s Board of Directors announced Belén Garijo as the company’s next CEO following the move to not renew the tenure of ...

PHARMAP 2026 addresses this transformation with a specialised session on patient-friendly design and its role in modern medicine. The event is scheduled for 20-21 April in Amsterdam. Trust and ...

An experimental Sanofi drug helped improve the neurological problems seen with a rare disease, as the company plans to seek ...

Feb 2 (Reuters) - Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more ...

At Sanofi, AI has shifted from experimentation to becoming a vital part of our infrastructure.